Kristina Kuhbandner
@kkuhbandner.bsky.social
PostDoc at University Hospital Heidelberg, scientific writer with special interest in cancer and neurosciences, love nature
Super happy to see this amazing work finally online. I hope this great tool will be used to advance leukemia research and improve patient care.
🚨 New preprint alert! 🚨
We just posted our latest manuscript on patient-derived xenograft (PDX) models in acute myeloid leukemia (AML):
📝 "A platform of robust patient-derived leukemia models covering subgroups for which no cell lines exist"
www.biorxiv.org/content/10.1...
Why this matters ⬇️
We just posted our latest manuscript on patient-derived xenograft (PDX) models in acute myeloid leukemia (AML):
📝 "A platform of robust patient-derived leukemia models covering subgroups for which no cell lines exist"
www.biorxiv.org/content/10.1...
Why this matters ⬇️
A platform of robust patient-derived leukemia models covering subgroups for which no cell lines exist
Preclinical cancer research requires robust model systems, especially for poor prognosis entities like acute myeloid leukemia (AML), a highly aggressive blood cancer. Here, primary tumor cells from 13...
www.biorxiv.org
September 29, 2025 at 9:56 AM
Super happy to see this amazing work finally online. I hope this great tool will be used to advance leukemia research and improve patient care.
Reposted by Kristina Kuhbandner
🚨 New preprint alert! 🚨
We just posted our latest manuscript on patient-derived xenograft (PDX) models in acute myeloid leukemia (AML):
📝 "A platform of robust patient-derived leukemia models covering subgroups for which no cell lines exist"
www.biorxiv.org/content/10.1...
Why this matters ⬇️
We just posted our latest manuscript on patient-derived xenograft (PDX) models in acute myeloid leukemia (AML):
📝 "A platform of robust patient-derived leukemia models covering subgroups for which no cell lines exist"
www.biorxiv.org/content/10.1...
Why this matters ⬇️
A platform of robust patient-derived leukemia models covering subgroups for which no cell lines exist
Preclinical cancer research requires robust model systems, especially for poor prognosis entities like acute myeloid leukemia (AML), a highly aggressive blood cancer. Here, primary tumor cells from 13...
www.biorxiv.org
September 29, 2025 at 9:44 AM
🚨 New preprint alert! 🚨
We just posted our latest manuscript on patient-derived xenograft (PDX) models in acute myeloid leukemia (AML):
📝 "A platform of robust patient-derived leukemia models covering subgroups for which no cell lines exist"
www.biorxiv.org/content/10.1...
Why this matters ⬇️
We just posted our latest manuscript on patient-derived xenograft (PDX) models in acute myeloid leukemia (AML):
📝 "A platform of robust patient-derived leukemia models covering subgroups for which no cell lines exist"
www.biorxiv.org/content/10.1...
Why this matters ⬇️
Reposted by Kristina Kuhbandner
Our recent lab trip to Oberammergau was the perfect mix of adventure, fresh mountain air, and team spirit 🌲💧. Exploring together and sharing new experiences outside the lab made this a truly memorable summer day! #acute#leukemia#research
August 21, 2025 at 1:48 PM
Our recent lab trip to Oberammergau was the perfect mix of adventure, fresh mountain air, and team spirit 🌲💧. Exploring together and sharing new experiences outside the lab made this a truly memorable summer day! #acute#leukemia#research
Looking forward to this great event and to discussing our research 😀
If you’re attending, don’t miss our posters! We’ll be sharing our latest research using genetically engineered Acute Leukemia PDX models—and we’d love to connect with you.
P18 @kkuhbandner.bsky.social
A novel Decitabine analogue with enhanced anti-leukemia activity and reduced toxicity in vivo
P18 @kkuhbandner.bsky.social
A novel Decitabine analogue with enhanced anti-leukemia activity and reduced toxicity in vivo
September 14, 2025 at 6:28 AM
Looking forward to this great event and to discussing our research 😀
Reposted by Kristina Kuhbandner
🚀 The 12th International Heidelberg Symposium on Stem Cells and Cancer – SCC2025 kicks off today!
The @jeremiaslab.bsky.social is thrilled to join leading experts to explore groundbreaking advances in the cancer stem cell field and spark new discussions.
stem-cells-cancer.de/event/scc2025/
The @jeremiaslab.bsky.social is thrilled to join leading experts to explore groundbreaking advances in the cancer stem cell field and spark new discussions.
stem-cells-cancer.de/event/scc2025/
12th International Heidelberg Symposium on Stem Cells and Cancer – SCC2025 | stem-cells-cancer.de
stem-cells-cancer.de
September 14, 2025 at 6:07 AM
🚀 The 12th International Heidelberg Symposium on Stem Cells and Cancer – SCC2025 kicks off today!
The @jeremiaslab.bsky.social is thrilled to join leading experts to explore groundbreaking advances in the cancer stem cell field and spark new discussions.
stem-cells-cancer.de/event/scc2025/
The @jeremiaslab.bsky.social is thrilled to join leading experts to explore groundbreaking advances in the cancer stem cell field and spark new discussions.
stem-cells-cancer.de/event/scc2025/
Reposted by Kristina Kuhbandner
🔬 @jeremiaslab.bsky.social is excited to attend the XXXVI. Kind-Philipp-Meeting! Irmela, @sercoz.bsky.social and Dhruv Mehra are on their way to Wilsede.
www.kind-philipp-meeting.de
Looking forward to an engaging program and to meeting experts and early career researchers in paediatric cancer!
www.kind-philipp-meeting.de
Looking forward to an engaging program and to meeting experts and early career researchers in paediatric cancer!
Welcome
Kind-Philipp-Foundation for Research in Pediatric Oncology XXXVI. Annual Meeting 4th-7th of June 2025
Dear Colleagues,
After yet another excellent Kind-Philipp-Meeting in 2024, we are looking forwa...
www.kind-philipp-meeting.de
June 4, 2025 at 1:40 PM
🔬 @jeremiaslab.bsky.social is excited to attend the XXXVI. Kind-Philipp-Meeting! Irmela, @sercoz.bsky.social and Dhruv Mehra are on their way to Wilsede.
www.kind-philipp-meeting.de
Looking forward to an engaging program and to meeting experts and early career researchers in paediatric cancer!
www.kind-philipp-meeting.de
Looking forward to an engaging program and to meeting experts and early career researchers in paediatric cancer!
Reposted by Kristina Kuhbandner
📢 We’re heading to Dublin!
Irmela Jeremias will be attending the 4th Translational Research Conference: Acute Lymphoblastic Leukaemia (ALL).
We’re excited to share our latest research during the poster session.
#ESHALL2025 #LeukemiaResearch #CRISPR #PDXmodels #TranslationalResearch
Irmela Jeremias will be attending the 4th Translational Research Conference: Acute Lymphoblastic Leukaemia (ALL).
We’re excited to share our latest research during the poster session.
#ESHALL2025 #LeukemiaResearch #CRISPR #PDXmodels #TranslationalResearch
May 21, 2025 at 2:43 PM
📢 We’re heading to Dublin!
Irmela Jeremias will be attending the 4th Translational Research Conference: Acute Lymphoblastic Leukaemia (ALL).
We’re excited to share our latest research during the poster session.
#ESHALL2025 #LeukemiaResearch #CRISPR #PDXmodels #TranslationalResearch
Irmela Jeremias will be attending the 4th Translational Research Conference: Acute Lymphoblastic Leukaemia (ALL).
We’re excited to share our latest research during the poster session.
#ESHALL2025 #LeukemiaResearch #CRISPR #PDXmodels #TranslationalResearch
Reposted by Kristina Kuhbandner
Looking forward to connecting with fellow pediatricians and presenting our latest findings on patient-derived xenograft models for AML.
🗣️ Don't miss Irmela‘s talk about "Serially transplantable PDX models for AML subtypes for which no cell lines exist“
🗣️ Don't miss Irmela‘s talk about "Serially transplantable PDX models for AML subtypes for which no cell lines exist“
May 9, 2025 at 12:20 PM
Looking forward to connecting with fellow pediatricians and presenting our latest findings on patient-derived xenograft models for AML.
🗣️ Don't miss Irmela‘s talk about "Serially transplantable PDX models for AML subtypes for which no cell lines exist“
🗣️ Don't miss Irmela‘s talk about "Serially transplantable PDX models for AML subtypes for which no cell lines exist“
Reposted by Kristina Kuhbandner
🎉 We’re excited to share our latest research on FLT3-targeted antibody-drug conjugates (ADCs) as a promising strategy to eliminate leukemic stem cells in AML! 🚀🔬Many thanks to all involved in this great BMBF-funded project #leukemia #PDXmodels
📖Read more here: www.nature.com/articles/s41...
📖Read more here: www.nature.com/articles/s41...
Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates - Leukemia
Leukemia - Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates
www.nature.com
February 3, 2025 at 3:33 PM
🎉 We’re excited to share our latest research on FLT3-targeted antibody-drug conjugates (ADCs) as a promising strategy to eliminate leukemic stem cells in AML! 🚀🔬Many thanks to all involved in this great BMBF-funded project #leukemia #PDXmodels
📖Read more here: www.nature.com/articles/s41...
📖Read more here: www.nature.com/articles/s41...
Hi everyone!
Happy to join the Bluesky community and connect 🙂.
Happy to join the Bluesky community and connect 🙂.
January 19, 2025 at 10:17 AM
Hi everyone!
Happy to join the Bluesky community and connect 🙂.
Happy to join the Bluesky community and connect 🙂.